Abstract
1733
Objectives This study evaluates the chitosan/β-glycero-phosphate (C/GP) thermosensitive formulation as the basis for local radiotherapy and chemotherapy of hepatoma treatment in the SD rat model.
Methods A total of 107/0.1 ml N1-S1 cells were inoculated in the right lobe of the liver sublayer in male SD rats. After growing for 1-2 weeks, a concentration of approximately 1.0×107 cells per ml was established. The hepatoma model used one of the following: (1) normal saline (0.1 mL), (2) C/GP hydrogel alone, (3) C/GP/188Re-Tincolloid (1 mCi/0.1 mL), and (4) C/GP/188Re-Tincolloid/Doxorubicin (Dox) (1 mCi 0.5 mg/0.1 mL). Survival curve examination was performed to determine the best model and its potential to treat liver cancer was evaluated for 30 days. The tumor growth curves were measured in all groups to evaluate survival time. Planar scintigraphy was performed at 1, 24, and 48 hours to monitor the local delivery of 188Re-Tincolloid combined with the hydrogel matrix. Sixty days after administration, the rats were sacrificed to perform blood analysis (CBC, WBC count, serum enzymes) and histology.
Results Tumor growth rates were demonstrated on the control, C/GP hydrogel, and C/GP/188Re-Tincolloid groups. The C/GP hydrogel-treated group had slower tumor growth rate than the control. However, the C/GP/188Re-Tincolloid group had excellent inhibition of tumor growth rate than the C/GP hydrogel group. Regarding survival time, the initial results of control and C/GP hydrogel groups were slower. The latter had a better survival rate than the control group. Histological estimation demonstrated that the C/GP/188Re-Tincolloid group had more necrosis and apoptosis of the hepatoma than the control group.
Conclusions Administration in situ thermosensitivity C/GP formulation with 188Re-Tincolloid provided the best therapeutic effect. We expect better inhibition of tumor growth with C/GP/188Re-Tincolloid/Dox than C/GP/188Re-Tincolloid in further studies because of the chemotherapeutic effects